TREAT CTC
BIG 1-12
TRastuzumab in HER2-negative Early breast cancer as Adjuvant Treatment for Circulating Tumor Cells (CTC)
Contenu de va-et-vient
This study is coordinated and sponsored by the EORTC, in collaboration with BCG, SUCCESS, UNICANCER and under the umbrella of the Breast International Group.
Pharmaceutical partners: Roche, Janssen Diagnostics
This study is funded by an educational grant from Roche and run under BIG’s Principles of Research Conduct.
More To Explore
DECRESCENDO
DECRESCENDO BIG 19-02 De-Escalation of adjuvant ChemotheRapy in HER2-positive, EStrogen reCEptor-negative, Node-negative early breast cancer patients who achieved pathological complete response after neoadjuvant chemotherapy and Dual HER2 blOckade Share